Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 20;135(46):17573-84.
doi: 10.1021/ja409510d. Epub 2013 Nov 6.

Geometric and electronic structure of the Mn(IV)Fe(III) cofactor in class Ic ribonucleotide reductase: correlation to the class Ia binuclear non-heme iron enzyme

Affiliations

Geometric and electronic structure of the Mn(IV)Fe(III) cofactor in class Ic ribonucleotide reductase: correlation to the class Ia binuclear non-heme iron enzyme

Yeonju Kwak et al. J Am Chem Soc. .

Abstract

The class Ic ribonucleotide reductase (RNR) from Chlamydia trachomatis (Ct) utilizes a Mn/Fe heterobinuclear cofactor, rather than the Fe/Fe cofactor found in the β (R2) subunit of the class Ia enzymes, to react with O2. This reaction produces a stable Mn(IV)Fe(III) cofactor that initiates a radical, which transfers to the adjacent α (R1) subunit and reacts with the substrate. We have studied the Mn(IV)Fe(III) cofactor using nuclear resonance vibrational spectroscopy (NRVS) and absorption (Abs)/circular dichroism (CD)/magnetic CD (MCD)/variable temperature, variable field (VTVH) MCD spectroscopies to obtain detailed insight into its geometric/electronic structure and to correlate structure with reactivity; NRVS focuses on the Fe(III), whereas MCD reflects the spin-allowed transitions mostly on the Mn(IV). We have evaluated 18 systematically varied structures. Comparison of the simulated NRVS spectra to the experimental data shows that the cofactor has one carboxylate bridge, with Mn(IV) at the site proximal to Phe127. Abs/CD/MCD/VTVH MCD data exhibit 12 transitions that are assigned as d-d and oxo and OH(-) to metal charge-transfer (CT) transitions. Assignments are based on MCD/Abs intensity ratios, transition energies, polarizations, and derivative-shaped pseudo-A term CT transitions. Correlating these results with TD-DFT calculations defines the Mn(IV)Fe(III) cofactor as having a μ-oxo, μ-hydroxo core and a terminal hydroxo ligand on the Mn(IV). From DFT calculations, the Mn(IV) at site 1 is necessary to tune the redox potential to a value similar to that of the tyrosine radical in class Ia RNR, and the OH(-) terminal ligand on this Mn(IV) provides a high proton affinity that could gate radical translocation to the α (R1) subunit.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) NRVS spectra of the MnIVFeIII cofactor; and representative simulations for structures having (b) two carboxylate bridges (bridging E227); (c) one carboxylate bridge (terminal E227) with FeIII at site 1; and (d) one carboxylate bridge (terminal E227) with MnIV at site 1.
Figure 2
Figure 2
(Left) Spectra obtained from NRVS (experimental, top; simulated, bottom) and (Right) related core motions contributing to the features in the simulated spectrum.
Figure 3
Figure 3
Abs, CD and MCD spectra of the MnIVFeIII cofactor in Ct RNR-β (R2). The arrows indicate the energies where the VTVH data were collected, and the * indicates a minor heme contaminant in the sample.
Figure 4
Figure 4
VTVH data for different bands, as indicated in Figure 3. Fits producing |D| = 2.3 cm−1E/D = 0.33 are shown as black lines.
Figure 5
Figure 5
(Left) Comparison of the energies of the calculated d-d transitions (from TD-DFT) for four different structural models of the MnIVFeIII cofactor (a–d) and the experimental d-d transitions from MCD spectra, and (Right) relative MnIV d orbital energies for each structural model.
Figure 6
Figure 6
LMCT Abs spectra of MnIVFeIII RNR-β (the three lowest CT bands are labeled bands 5–7) correlated to TD-DFT calculated µ-oxo → MnIV (blue), terminal OH → MnIV (green) and µ-oxo → FeIII (red) CT transitions for two possible structures, with either OH or H2O as the terminal ligand on Mn at site 1. The orbitals for (i), (ii), (iii) transitions are shown in Figure 7 (vide infra).
Figure 7
Figure 7
LMCT processes associated with pseudo-A term features. For pseudo-A term MCD behavior, there must be 2 perpendicular CT transitions and SOC along a 3rd mutually-orthogonal direction. SOC is a single center 1e operator. Therefore, 2 CTs must be “from” the same orbital or “to” the same orbital. Among the CT transitions in the TD-DFT calculations, there are 3 transitions (i, ii, iii) involving orbitals which could SOC via a 3rd perpendicular direction. For Mn-centered transitions, the terminal OH → Mn CT transition is x-polarized, and the µ-oxo → Mn CT transition is z-polarized. The ligand donor orbitals are mixed with dxy and dyz, which SOC via Ly (bottom left). For µ-oxo ligand-centered transitions, the CT to Mn is z-polarized and the transition to Fe is y-polarized. These metal d orbitals are mixed with the Opz and Opy ligand orbitals, which SOC via Lx (bottom right)
Figure 8
Figure 8
Calculated ZFS tensor orientation and intensity for the MnIVFeIII cofactor. Initial ZFS orientation is shown with blue dotted arrows, where x and y orientations rotate to red arrows due to the antisymmetric ZFS arising from hetero-bimetallic center.
Figure 9
Figure 9
DFT-optimized structural model for the MnIVFeIII cofactor from this study.
Scheme 1
Scheme 1
(a) Function of the MnIVFeIII cofactor in catalysis by a class Ic ribonucleotide reductase: substrate reduction in α (R1) following radical initiation by MnIVFeIII cofactor in β (R2) through a radical-translocation process; (b) structure of the MnIVFeIII cofactor site in class Ic ribonucleotide reductase (x = 1 or 2, M1 = metal site 1, and M2 = metal site 2); and (c) structure of the FeIIIFeIV intermediate X in class Ia ribonucleotide reductase (x = 1 or 2).

Similar articles

Cited by

References

    1. Jordan A, Reichard P. Annu. Rev. Biochem. 1998;67:71–98. - PubMed
    1. Stubbe J. Curr. Opin. Chem. Biol. 2003;7:183–188. - PubMed
    1. Nordlund P, Reichard P. Annu. Rev. Biochem. 2006;75:681–706. - PubMed
    1. Stubbe J, Nocera DG, Yee CS, Chang MCY. Chem. Rev. 2003;103:2167–2202. - PubMed
    1. Reece SY, Hodgkiss JM, Stubbe J, Nocera DG. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2006;361:1351–1364. - PMC - PubMed

Publication types